Profile: Stemline Therapeutics Inc (STML.OQ)
29 Mar 2017
Stemline Therapeutics, Inc., incorporated on August 8, 2003, is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.
SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. Mechanistically, the IL-3 domain of SL-401 directs its cytotoxic payload to IL-3R+ cells. SL-401 is then internalized by target cells, leading to intracellular release of the payload, inhibition of protein synthesis and cell death, or apoptosis. In Acute myeloid leukemia (AML), SL-401 is active against both leukemia blasts (tumor bulk) and CSCs of various human leukemia cell lines and primary leukemia cells from patients. SL-401 also exhibited anti-CSC activity. SL-401 has been granted Orphan Drug designation from the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of Blastic plasmacytoid dendritic cell neoplasm (BPDCN) and AML.
SL-701 includes various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. The Company is conducting Phase II trial of SL-701. SL-701 has been awarded Orphan Drug designation from the United States Food and Drug Administration (FDA) for the treatment of glioma.
The Company competes with Merck & Co., Inc., Eisai Co., Inc., Roche Holding AG and Karyopharm Therapeutics, Inc.
Stemline Therapeutics Inc
750 Lexington Ave
NEW YORK NY 10022-1200
Company Web Links
- BRIEF-Stemline Therapeutics reports completion of enrollment in stage 3 sl-401 pivotal trial in BPDCN
- BRIEF-Stemline Therapeutics Q4 loss per share $0.56
- BRIEF-Stemline Therapeutics provides update on pivotal BPDCN trial
- BRIEF-Stemline Therapeutics reports oral presentation of sl-701 phase 2 data in second-line glioblastoma at the 21st annual meeting of the society of neuro-oncology (sno)
- BRIEF-Stemline Therapeutics reports Q3 financial results